Inventprise, LLC

26 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Apr 2033

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due May 7, 2027
The maintenance fee for Just-in-time bioprocess plant system (US 11,809,172) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
1 fee due Jul 23, 2027
The maintenance fee for VLP Stabilized Vaccine Compositions (US 11,878,054) comes due Jul 23, 2027. Unpaid by Jan 24, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,957,485	Systems and methods for virus propagation in cell cultures for vaccine manufacture In force Term ends Apr 18, 2033 · From the USPTO record	In force	Term ends Apr 18, 2033	From the USPTO record
US 9,452,213	Genetically detoxified pertussis vaccine that maintains intrinsic adjuvant activity In force Term ends Jul 15, 2035 · From the USPTO record	In force	Term ends Jul 15, 2035	From the USPTO record
US 9,821,056	Genetically detoxified pertussis vaccine that maintains intrinsic adjuvant activity In force Term ends Jul 15, 2035 · From the USPTO record	In force	Term ends Jul 15, 2035	From the USPTO record
US 10,076,563	Bordetella pertussis immunogenic vaccine compositions In force Term ends Apr 18, 2036 · From the USPTO record	In force	Term ends Apr 18, 2036	From the USPTO record
US 10,751,404	Bordetella pertussis immunogenic vaccine compositions In force Term ends Apr 18, 2036 · From the USPTO record	In force	Term ends Apr 18, 2036	From the USPTO record
US 10,758,606	VLP Stabilized Vaccine Compositions In force Term ends Sep 6, 2036 · High confidence	In force	Term ends Sep 6, 2036	High confidence
US 11,878,054	VLP Stabilized Vaccine Compositions In force Term ends Sep 6, 2036 · High confidence	In force	Term ends Sep 6, 2036	High confidence
US 12,318,440	VLP Stabilized Vaccine Compositions In force Term ends Sep 6, 2036 · Medium confidence	In force	Term ends Sep 6, 2036	Medium confidence
US 10,159,728	Multivalent VLP conjugates In force Term ends Sep 12, 2036 · From the USPTO record	In force	Term ends Sep 12, 2036	From the USPTO record
US 10,736,952	Multivalent VLP conjugates In force Ends no later than Sep 12, 2036 · From the USPTO record	In force	Ends no later than Sep 12, 2036	From the USPTO record

10 of 26 patents shown.

Pro members see all 26.

Pro members: see all 26 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 1 abandoned · 3 no status recorded

List them